Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that followed a six-month decline in the stock price.

With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.

Platforms using natural language processing are showing promise in scanning patients' records for biomarkers and other enrollment criteria for clinical trials.

Scientists have collected troves of DNA and microscopic imaging data from human cells—and now they have a tool that might ...

Over a video call, Alex Zhavoronkov holds up a small, green, diamond-shaped pill. It has been developed by his company to ...

At both Biotech Showcase and RESI JPM, BullFrog AI will highlight its proprietary BullFrog Data Networks ®, a data insights tool powered by the bfLEAP™ platform. BullFrog Data Networks ® evaluate high ...

Partnership Will Harness NYSCF's Automated Cell Culture Systems and Artificial Intelligence Capabilities to Study Disease at ...

Novo Nordisk on Wednesday announced an expanded deal with healthtech firm Valo Health to use AI to fuel drug discovery.

Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop ...

Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.

The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other ...